TRL-345 is under clinical development by Trellis Bioscience and currently in Phase I for Cytomegalovirus (HHV-5) Infections. According to GlobalData, Phase I drugs for Cytomegalovirus (HHV-5) Infections have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TRL-345’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRL-345 overview
TRL-345 (CMV-345) is under development for the treatment of human cytomegalovirus infections. The drug candidate acts by targeting HCMV glycoprotein B (gB). It is developed based on the CellSpot technology. It is administered through intravenous route.
Trellis Bioscience overview
Trellis Bioscience (Trellis), formerly Trellis Bioscience, is a drug development company that discovers and develops human antibody therapeutics for the treatment of bacterial and viral infectious diseases and cancer indications. Its clinical candidate includes TRL1068, which targets and disintegrates bacterial biofilm. The company develops CellSpot technology to find rare human antibodies that are identified and recovered from human blood cells. Its antibodies can be applied in the treatment of infectious disease such as respiratory syncytial virus, cytomegalovirus, auto-immune diseases, Influenza and cancer. The company provides pipeline of therapies in bacterial, viral, and cancer indications. It operates through government and philanthropic institutions, biotech and pharma companies. Trellis is headquartered in Menlo Park, California, the US.
For a complete picture of TRL-345’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
